Recurrent and/or metastatic thyroid cancer: therapeutic options

Bibliography

• PARKIN DM, MUIR CS, WHELAN SL, GAO YT, FERLAY J, POWELL J: Cancer incidence in five continents. Vol. 6. International Agency for Research on Cancer. Lyon, France (1992).
   Google Scholar
• SCHLUMBERGER MJ: Papillary and follicular thyroid carcinoma. N Engl. J. Med. (1998) 338(5):297–306.
   PubMed Web of Science ®Google Scholar
• ••A thorough review on differentiatedthyroid cancer.
   Google Scholar
• FRANCES CHI S, BOYLE P, MAISONNEUVE P et al: The epidemiology of thyroid carcinoma. Cr. Rev in Oncogenesis (1993) 4:25–52.
   PubMedGoogle Scholar
• SCHLUMBERGER M, PACINI F: Epidemiology. In: Thyroid Tumours. M. Schlumberger, Furio Pacini (eds), Editions Nucleon, Paris, France (1999):47–59.
   Google Scholar
• HEDINGER C, WILLIAMS ED, SOBIN LH: Histological typing of thyroid tumours. In: International Histological classification of tumours. World Health Organization, Springer-Verlang, Berlin, Germany (1988):Vol 11.
   Google Scholar
• LIVOLSI VA: Papillary lesions of the thyroid. In: Surgical Pathology of the Thyroid LiVolsi VA, Bennington JL (eds), WB Saunders Co, Philadelphia, PA, USA (1990):136–172.
   Google Scholar
• LIVOLSI VA: Follicular lesions of the thyroid. In: Surgical Pathology of the Thyroid LiVolsi VA, Bennington JL (eds), WB Saunders Co, Philadelphia, PA, USA (1990):173–212.
   Google Scholar
• GIUFFRIDA D, GHARIB H: Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann. Oncol. (2000) 11:1083–1089.
   PubMed Web of Science ®Google Scholar
• CADY B, ROSSI R: An expanded view ofrisk-group definition in differentiated thyroid carcinoma. Surgery (1988) 104:947–953.
   PubMed Web of Science ®Google Scholar
• DE GROOT LJ, KAPLAN EL, MCCORMICK M, STRAUS FH: Natural history, treatment and course of papillary thyroid carcinoma. I Clin. Endocrinol. Metab. (1990) 71:414–424.
   PubMed Web of Science ®Google Scholar
• HAY ID, BERGSTRALH EF, GOELLNER JR, EBERS OLD JR, GRANT CS: Predicting outcome of papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery (1993) 114:1050–1058.
   PubMed Web of Science ®Google Scholar
• •An interesting paper concerning a great number of patients.
   Google Scholar
• BIERLEY ID, PANZARELLA T, TSANG RW, GOSPODAROWICZ MK, 0' SULLIVAN B: A comparison of different staging systems predictability of patient outcome: thyroid carcinoma as an example. Cancer (1997) 79:2414–2423.
   PubMedGoogle Scholar
• MAZZAFERRI EL, JHIANG SM: Long-term impact of initial surgery and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. (1994) 97:418–428.
   PubMed Web of Science ®Google Scholar
• HERMANEK P, SOBIN LH: Thyroid gland. In: TMN classification of malignant tumors. Hermanek P, Sobin LH (eds), Springer-Verlang, Berlin, Germany (1992):35–37.
   Google Scholar
• LOH KC, GREENSPAN FS, GEE L MILLER T, YEO P: Pathological tumor-node-metastasis (pTNIA) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab. (1997) 82:3553–3562.
   PubMed Web of Science ®Google Scholar
• ••A retrospective evaluation of the TNMstaging system for prognosis and therapy.
   Google Scholar
• MAZZAFERI EL, KLOOS RT: Current approaches to primary therapy for papillary and follicular thyroid cancer. Clin. Endocrinol. Metab. (2001) 86:1447–1463.
   Google Scholar
• ••A detailed review of primary therapy ofdifferentiated thyroid cancer.
   Google Scholar
• SAMAAN NA, SCHULTZ PN, HICKEY RC et al: The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. I Clin. Endocrinol. Metab. (1992) 75:714–720.
   PubMed Web of Science ®Google Scholar
• •A retrospective review of treatment of differentiated thyroid cancer.
   Google Scholar
• PUJOL P, DAURES JP, NSAKALA N et al: Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. j. Clin. Endocrinol. Metab. (1996) 81:4318–4323.
   PubMed Web of Science ®Google Scholar
• COOPER DS, SPECKER B, HO M et al:Thyrotropin suppression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid (1998) 8:737–744.
   PubMed Web of Science ®Google Scholar
• THYROID CARCINOMA TASK FORCE: AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. End Practice. (2001) 7:202–220.
   Google Scholar
• ••A comprehensive approach to thetreatment of thyroid cancer.
   Google Scholar
• GREENSPAN SL, GREENSPAN FS: The effect of thyroid hormone on skeletal integrity. Ann. Intern. Med. (1999) 130:750–758.
   PubMed Web of Science ®Google Scholar
• BIONDI B, FAZIO S, COLTORTI F et al.: Reentrant atrioventricular nodal tachycardia induced by levothyroxine. Endocrinol. Metab. (1998) 83:2643–2645.
   Google Scholar
• BIONDI B, FAZIO S, CUOCOLO A et al.: Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. I Gin. Endocrinol. Metab. (1996) 81:4224–4228.
   PubMed Web of Science ®Google Scholar
• RINGEL MD, BALDUCCI-SILANO PL, ANDERSON JS et al.: Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma. I Clin. Endocrinol. Metab. (1999) 84:4037–4042.
   PubMedGoogle Scholar
• BOJUNGAJ, RODDIGER S, STANISCH M et al.: Molecular detection of thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease by RT-PCR. Br. J. Cancer. (2000) 82:1650–1655.
   PubMedGoogle Scholar
• MAZZAFERRI E: An overview of the management of papillary and follicular thyroid carcinoma. Thyroid (1999) 9:421–427.
   PubMedGoogle Scholar
• ••A useful paper for the management ofdifferentiated thyroid cancer.
   Google Scholar
• HAIGH IP, ITUARTE PH, WU HS et Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer (2001) 91:2335–2342.
   PubMed Web of Science ®Google Scholar
• GORETZKI PE, SIMON D, FRILLING A et al.: Surgical reintervention for differentiated thyroid cancer. Br. .1. &rig. (1993) 80:1009–1012.
   Google Scholar
• MAXON HR, SMITH HS: Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol. Metab. Clin. North. Am. (1990) 19:685–718.
   PubMed Web of Science ®Google Scholar
• ••A detailed review of radioiodine-131applications in thyroid cancer.
   Google Scholar
• VANNOSTRAND D, NEUTZE J, ATKINS F: Side effects of 'rational dose' iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J. Nucl. Med. (1986) 27:1519–1527.
   PubMedGoogle Scholar
• KOONG SS, REYNOLDS JC, MOVIUS EG et al.: Lithium as a potential adjuvant to 1131 therapy of metastatic, well differentiated thyroid carcinoma. I. Clin. Endocrinol. Metab. (1999) 84:912–916.
   PubMed Web of Science ®Google Scholar
• LEGER FA, IZEMBART M, DAGOUSSET F et al.: Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Ear: J. Nucl. Med. (1998) 25:242–246.
   Google Scholar
• PARK HM, PARK YH, ZHOU XH: Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid (1997) 7:277–80.
   PubMedGoogle Scholar
• CHOLEWINSKI SP, Y00 KS, KLIEGER PS, O'MARA RE: Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 1311.1. Nucl. Med. (2000) 41:1198–1202.
   Google Scholar
• PACINI F, LIPPI F, FORMICA N et al.:Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. Nucl. Med. (1987) 28:1888–1891.
   Google Scholar
• SCHLUMBERGER M, ARCANGIOLI O, PIEKARSKI JD, TUBIANA M PARMENTIER C: Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J. Nucl. Med. (1988) 29:1790–1794.
   PubMed Web of Science ®Google Scholar
• PINEDA JD, LEE T, AIN K, REYNOLDSJC, ROBBINS J: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. Endocrinol. Metab. (1995) 80:1488–1492.
   Google Scholar
• PACINI F, CETANI F, MICOLI P et al: Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World &rig. (1994) 18:600–604.
   Google Scholar
• ••An interesting analysis of radioiodinetreatment outcome.
   Google Scholar
• SIMPSON WJ, PANZARELLA T, CARRUTHERS JC, GOSPODARO-WICZ MK, SUTCLIFFE SB: Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int. Radiat. Oncol. Biol. Phys. (1988) 14:1063–1075.
   PubMed Web of Science ®Google Scholar
• TUBIANA M, HADDAD E, SCHLUMBERGER M, HILL C, ROUGIER P, SARRAZIN D: External radiotherapy in thyroid cancers. Cancer (1985) 55:2062–2071.
   PubMed Web of Science ®Google Scholar
• ROSS DS: Long-term management of differentiated thyroid cancer. Endocrinol. Metab. North Am. (1990) 19:719–739.
   PubMedGoogle Scholar
• KIM JH, LEEPER RD: Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer (1987) 60:2372–2375.
   PubMed Web of Science ®Google Scholar
• SCHLUMBERGER M, TUBIANA M, DE VATHAIRE F et al.: Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. (1986) 63:960–967.
   Google Scholar
• •An interesting evaluation of treatment outcome in metastatic thyroid cancer.
   Google Scholar
• DOTTORINI ME, VIGNATI A, MAZZUCCHELLI L, LOMUSCIO G, COLOMBO L: Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J. Nucl. Med. (1997) 38:669–675.
   PubMedGoogle Scholar
• ••A comprehensive analysis of differentiatedthyroid cancer in children.
   Google Scholar
• LA QUAGLIA MP, BLACK T, HOLCOMB GW et al.: Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. I Pediatr. &rig. (2000) 35:955–959.
   Google Scholar
• CASARA D, RUBELLO D, SALADINI G et al.: Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. Nucl. Med. (1993) 34:1626–1631.
   Google Scholar
• SCHLUMBERGER M, CHALLETON C, DEVATHAIRE F et al.: Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. Nucl. Med. (1996) 37:598–605.
   Google Scholar
• •Assessment of radioiodine or external radiotherapy effects on metastatic thyroid cancer.
   Google Scholar
• NIEDERLE B, ROKA R, SCHEMPER M, FRITSCH A, WEISSEL M, RAMACH W: Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. Surgery (1986) 100:1088–1097.
   PubMed Web of Science ®Google Scholar
• PELIKAN DM, LION HL, HERMANS J, GROSLINGS BM: The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Clin. Endocrinol. (1997) 47:713–720.
   PubMedGoogle Scholar
• MAZZAFERRI EL: Editorial: treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? Clin. Endocrinol. Metab. (1995) 80:1485–1487.
   Google Scholar
• ••A critical editorial.
   Google Scholar
• DEKEIZER B, KOPPESCHAAR HP, ZELISSEN PM et al.: Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Ear: J. Nucl. Med. (2001) 28:198–202.
   Google Scholar
• SHERMAN SI, GOPAL J: Thyroglobulin positive, RAI nagative thyroid cancers: the role of conservative management. J. Endocrinol. Metab. (1998) 83:4199–4200.
   Google Scholar
• PACINI F, AGATE R, ELISEI M et al.: Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 1-131 whole body scan: comp-arison of patients treated with high 1-131 activities versus untreated patients. J. Endocrinol. Metab. (2001) 86:4092–4097.
   PubMed Web of Science ®Google Scholar
• •A detailed approach of various treatment modalities in patients with detectable thyroglobulin but negative total body scanning.
   Google Scholar
• VANTOL KM, HEW JM, JAGER PL, VERMEY A, DULLAART RPF, LINKS TP: Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin. Endocrinol. (2000) 52:653–659.
   PubMedGoogle Scholar
• SMIT JVVA, VIELVOYE GJ, GOSLINGS BM: Embolization for vertebral metastases of follicular thyroid carcinoma. J. Endocrinol. Metab. (2000) 85:989–994.
   Google Scholar
• DULGEROFF AJ, HERSHMAN JM: Medical therapy for differentiated thyroid carcinoma. Endocc Rev (1994) 15:500–515.
   PubMedGoogle Scholar
• ••A thorough review on medical therapy ofthyroid cancer.
   Google Scholar
• SHIMAOKA K, SCHOENFELD DA, DEWYS WD, CREECH RH, DECONTI R: A randomized trial of doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer (1985) 56:2155–2160.
   PubMed Web of Science ®Google Scholar
• MAHESHWARI YK, HILL CS, HAYNIE TP, HICKEY RC, SAMAAN NA: 1–131 therapy in differentiated thyroid carcinoma: M.D. Anderson hospital experience. Cancer (1981) 47:664–671.
   Google Scholar
• DEBESI P, BUSNARDO B, TOSO S et al.: Combined chemotherapy with bleomycin andriamycin and platinum in advanced thyroid cancer. J. Endocrinol Invest. (1991) 14:475–480.
   PubMedGoogle Scholar
• ZLOCK DW, GREENSPAN FS, CLARK OH, HIGGINS CB: Octreotide therapy in advanced thyroid cancer. Thyroid (1994) 4:427–431.
   PubMedGoogle Scholar
• GORGES R, KAHALY G, MULLER-BRAND J, MACKE H, ROSER H, BOCKISCH A: Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid (2001) 11:647–659.
   PubMed Web of Science ®Google Scholar
• LEEPER RD: The effect of 131 I therapy onsurvival of patients with metastatic papillary or follicular thyroid carcinoma. J. Endocrinol Metab. (1973) 36:1143–1152.
   PubMedGoogle Scholar
• ALLWEISS P, BRAUNSTEIN GD, KATZ A, WAXMAN: Sialadenitis following 1-131 therapy for thyroid carcinoma: concise communication. J. Nucl. Med. (1984) 25:755–758.
   PubMedGoogle Scholar
• PACINI F, GASPERI M, FUGAZZOLA L et al.: Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. Nucl. Med. (1994) 35:1418–1422.
   Google Scholar
• RAYMOND JP, IZEMBART M, MARLIAC V et al.: Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine." Clin. Endocrinol Metab. (1989) 69:186–190.
   Google Scholar
• SCHLUMBERGER M, DEVATHAIRE F, CECCARELLI C et al.: Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J. Nucl. Med. (1996) 37:606–612.
   PubMedGoogle Scholar
• EDMONDS CL, SMITH T: The long-term hazards of the treatment of thyroid cancer with radioiodine. Br. J. Radial. (1986) 59:45–51.
   PubMed Web of Science ®Google Scholar
• AIN KB: Anaplastic thyroid carcinoma: behavior, biology and therapeutic approaches. Thyroid (1998) 8:715–726.
   PubMed Web of Science ®Google Scholar
• ••A thorough review on anaplastic thyroidcancer.
   Google Scholar
• SAMAAN NA, ORDONEZ NG: Uncommon types of thyroid cancer. Endocrinol Metab. Clin. North Am. (1990) 19:637–648.
   PubMedGoogle Scholar
• DEMEURE MJ, CLARK OH: Surgery in the treatment of thyroid cancer. Endocrinol Metab. Gin. North Am. (1990) 19:663–684.
   PubMedGoogle Scholar
• KOBOYASHI T, ASAKAWA H, UMESHITA K et al: Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck (1996) 18:36–41.
   PubMedGoogle Scholar
• AIN KB, MERRILL JE, DESIMONE PA: Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase II trial using ninety-six-hour infusion. Thyroid (2000) 10:587–594.
   PubMed Web of Science ®Google Scholar
• BUSNARDO B, DANIELE O, PELIZZO MR et al.: A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.' Endocrinol Invest. (2000) 23:755–761.
   PubMedGoogle Scholar
• TENNVALL J, LUNDELL G, HALLQUIST A et al.: Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Cancer (1994) 74:1348–1354.
   PubMedGoogle Scholar
• TZAVARA I, VLASSOPOULOU B, ALE VIZAKI K et al.: Differentiated thyroid cancer: a retrospective analysis of 832 cases from Greece. Gin. Endocrinol (1999) 50:643–654.
   Google Scholar
• GHARIB H: The use of recombinant thyrotropin in patients with thyroid cancer. Endocrinologist (2000) 10:255–263.
   Google Scholar
• MAZZAFERRI EL, KLOOS RT: Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid (2000) 9:767–778.
   Google Scholar
• ••A thorough review on rhTSH.
   Google Scholar
• SCHLUMBERGER M, RICARD M, PACINI F: Clinical use of recombinant human TSH in thyroid cancer patients. Etm Endocrinol (2000) 143:557–563.
   Google Scholar
• •A useful evaluation of clinical uses of rhTSH.
   Google Scholar
• LIPPI F, CAPEZZONE M, ANGELINI F et al.: Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur. Endocrinol (2001) 144:5–11.
   PubMed Web of Science ®Google Scholar
• BERG G, LINDSTEDT G, SUURKULA M, JANSSON S: Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. j. Endocrinol Invest. (2002) 25:44–52.
   PubMed Web of Science ®Google Scholar
• LUSTER M, LASSMANN M, HAENSCHEID H, MICHALOWSKI U, INCERTI C, REINERS C: Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. Endocrinol Metab. (2000) 85:3640–3645.
   Google Scholar
• SCHMUTZLER C, KOHRLE J: Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid (2000) 10:393–406.
   PubMed Web of Science ®Google Scholar
• ••A detailed review on retinoic acid therapyin thyroid cancer.
   Google Scholar
• AIN KB: Management of undifferentiated thyroid cancer. Bailliere' s Clin. Endocrinol Metab. (2000) 14:615–629.
   PubMedGoogle Scholar
• ••A valuable analysis on the management ofundifferentiated thyroid cancer.
   Google Scholar
• NISHIHARA E, NAGAYAMA Y, MAWATARI F et al.: Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology (1997) 138:4577–4583.
   PubMed Web of Science ®Google Scholar